introduction to the bayesian continual reassessment method...
TRANSCRIPT
![Page 1: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/1.jpg)
Introduction to the Bayesian continualreassessment method (CRM) for phase one clinical
trials
JoAnn Alvarez, [email protected]
Department of BiostatisticsCenter for Quantitative Sciences
Vanderbilt University School of Medicine
2013 October 11
![Page 2: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/2.jpg)
introductionmodel
variations on CRM
Overview
1 introduction
2 model
3 variations on CRM
J. Alvarez Bayesian CRM
![Page 3: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/3.jpg)
introductionmodel
variations on CRM
Phase 1 goal
Find the right dose
J. Alvarez Bayesian CRM
![Page 4: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/4.jpg)
introductionmodel
variations on CRM
The higher the dose,
the more efficaciousthe higher the toxicity
We balance efficacy and toxicity by choosing a targetedtoxicity level (TTL) (probability of toxicity)
Then find dose with targeted toxicity level: MTD, maximumtolerated dose
J. Alvarez Bayesian CRM
![Page 5: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/5.jpg)
introductionmodel
variations on CRM
The higher the dose,
the more efficaciousthe higher the toxicity
We balance efficacy and toxicity by choosing a targetedtoxicity level (TTL) (probability of toxicity)
Then find dose with targeted toxicity level: MTD, maximumtolerated dose
J. Alvarez Bayesian CRM
![Page 6: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/6.jpg)
introductionmodel
variations on CRM
The higher the dose,
the more efficaciousthe higher the toxicity
We balance efficacy and toxicity by choosing a targetedtoxicity level (TTL) (probability of toxicity)
Then find dose with targeted toxicity level: MTD, maximumtolerated dose
J. Alvarez Bayesian CRM
![Page 7: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/7.jpg)
introductionmodel
variations on CRM
Phase 1 design
Goal is to
get information about the best dose
treat each patient ethically
: with the treatment bestsupported by the current evidence
J. Alvarez Bayesian CRM
![Page 8: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/8.jpg)
introductionmodel
variations on CRM
Phase 1 design
Goal is to
get information about the best dose
treat each patient ethically: with the treatment bestsupported by the current evidence
J. Alvarez Bayesian CRM
![Page 9: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/9.jpg)
introductionmodel
variations on CRM
Design of phase one study involves best way to acheive:
get information about the best dose
treat each patient with the treatment best supported by thecurrent evidence
Main design issue is what dose to give each patient
J. Alvarez Bayesian CRM
![Page 10: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/10.jpg)
introductionmodel
variations on CRM
Basic idea of CRM
after each patient outcome is observed, dose-responserelationship is re-estimated
next patient is given the dose that is the current estimate ofthe MTD
J. Alvarez Bayesian CRM
![Page 11: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/11.jpg)
introductionmodel
variations on CRM
patients arrive sequentially
observation Yj on each patient is whether they have a toxicresponse
J. Alvarez Bayesian CRM
![Page 12: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/12.jpg)
introductionmodel
variations on CRM
Dose-response relationship
−1.5 −1.0 −0.5 0.0 0.5 1.0 1.5
0.0
0.2
0.4
0.6
0.8
1.0
Standardized dose
P(Y
= 1
| do
se =
x)
J. Alvarez Bayesian CRM
![Page 13: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/13.jpg)
introductionmodel
variations on CRM
Let θ be the TTL.
Objective is to find corresponding dose, x∗ (MTD)
J. Alvarez Bayesian CRM
![Page 14: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/14.jpg)
introductionmodel
variations on CRM
Dose-response model
Need a model for the dose-response relationship.
Choose any one-parameter function ψ(x, a), monotonic in xand a.
We assume that there exists an a0: ψ(x∗, a0) = θ
Can think of a0 as a population parameter
J. Alvarez Bayesian CRM
![Page 15: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/15.jpg)
introductionmodel
variations on CRM
since each patient gets the current best estimate of the MTD,more information is collected for values near the true MTD
model not expected/required to be accurate at doses far fromthe MTD
model expected to perform well near the MTD.
only need one-parameter model
J. Alvarez Bayesian CRM
![Page 16: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/16.jpg)
introductionmodel
variations on CRM
Objective is to find the value of a that gives x∗
a : ψ−1(θ, a0) = x∗
This value is a0.
J. Alvarez Bayesian CRM
![Page 17: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/17.jpg)
introductionmodel
variations on CRM
The model
We assume∀θ,∀x∗, ∃!a0 : ψ(x∗, a0) = θ.
J. Alvarez Bayesian CRM
![Page 18: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/18.jpg)
introductionmodel
variations on CRM
∀θ,∀x∗, ∃!a0 : ψ(x∗, a0) = θ.
−1.5 −1.0 −0.5 0.0 0.5 1.0 1.5
0.0
0.2
0.4
0.6
0.8
1.0
Standardized dose
ψ(a
, x)=
P(D
LT|d
ose
= x
)
x*
θ
J. Alvarez Bayesian CRM
![Page 19: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/19.jpg)
introductionmodel
variations on CRM
∀θ,∀x∗, ∃!a0 : ψ(x∗, a0) = θ.
−1.5 −1.0 −0.5 0.0 0.5 1.0 1.5
0.0
0.2
0.4
0.6
0.8
1.0
Standardized dose
ψ(a
, x)=
P(D
LT|d
ose
= x
)
x*
θ
J. Alvarez Bayesian CRM
![Page 20: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/20.jpg)
introductionmodel
variations on CRM
∀θ,∀x∗, ∃!a0 : ψ(x∗, a0) = θ.
−1.5 −1.0 −0.5 0.0 0.5 1.0 1.5
0.0
0.2
0.4
0.6
0.8
1.0
Standardized dose
ψ(a
, x)=
P(D
LT|d
ose
= x
)
x*
θ
a0 = ?
J. Alvarez Bayesian CRM
![Page 21: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/21.jpg)
introductionmodel
variations on CRM
Example dose-response curve family
ψ(x, a) =(tanh(x) + 1)a
2a
−1.5 −1.0 −0.5 0.0 0.5 1.0 1.5
0.0
0.2
0.4
0.6
0.8
1.0
Standardized dose
ψ(a
, x)=
P(D
LT|d
ose
= x
)
a0 = 0.1
a0= 0.3
a0= 0.5
a 0= 1
a 0= 5
J. Alvarez Bayesian CRM
![Page 22: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/22.jpg)
introductionmodel
variations on CRM
Dose-response models
logistic
hyperbolic tangent
power
J. Alvarez Bayesian CRM
![Page 23: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/23.jpg)
introductionmodel
variations on CRM
Dose-response models
Logistic model:
ψ(x, a) =e3+ax∗
1 + e3+ax∗
−3 −2 −1 0 1
0.0
0.2
0.4
0.6
0.8
1.0
Standardized dose
P(Y
= 1
| do
se =
x)
J. Alvarez Bayesian CRM
![Page 24: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/24.jpg)
introductionmodel
variations on CRM
Suppose the jth patient has enrolled and is ready to receivethe treatment.
The first j − 1 patients have observed response data:x(1) Y1x(2) Y2x(3) Y3
......
x(j − 1) Yj−1
Want to give patient j current best guess of MTD.
J. Alvarez Bayesian CRM
![Page 25: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/25.jpg)
introductionmodel
variations on CRM
Let the current posterior for a0 be fa0(a, data)
J. Alvarez Bayesian CRM
![Page 26: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/26.jpg)
introductionmodel
variations on CRM
Ways to estimate P(DLT) for each dose
Estimate P (Y = 1|x = xi):
Plug-in estimatorUsing the data from the first j − 1 patients, calculatethe posterior mean of a0.Plug it into ψ to get an updated dose-response curve.
Mean estimatorestimate the probability of toxicity it by its mean,integrating over all possible values of a0 at each dose.
P (Y = 1|x = xi) =
∫ ∞0
ψ(xi, a)fa0(a, data) da
J. Alvarez Bayesian CRM
![Page 27: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/27.jpg)
introductionmodel
variations on CRM
Choose next dose
Now that we have updated P (Y = 1|x = xi), we have to choosethe ‘best’ dose
J. Alvarez Bayesian CRM
![Page 28: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/28.jpg)
introductionmodel
variations on CRM
Choose next dose
Patient j’s dose, x(j), will be
dose that is closest to the the current estimate of the MTD:the dose that gives θ in the current estimate of ψdose that gives the estimated P(DLT) closest to the TTL, θ
Standardized dose
P(Y
= 1
| do
se =
x)
x*
θ
x1 x2 x3 x4
●
●
●
●
●
θ1^
θ2^
θ3^
θ4^
J. Alvarez Bayesian CRM
![Page 29: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/29.jpg)
introductionmodel
variations on CRM
Choose next dose
Patient j’s dose, x(j), will be
dose that is closest to the the current estimate of the MTD:the dose that gives θ in the current estimate of ψdose that gives the estimated P(DLT) closest to the TTL, θ
Standardized dose
P(Y
= 1
| do
se =
x)
x*
θ
x1 x2 x3 x4
●
●
●
●
●
θ1^
θ2^
θ3^
θ4^
J. Alvarez Bayesian CRM
![Page 30: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/30.jpg)
introductionmodel
variations on CRM
Observe patient j’s response, Yj : either toxicity or no toxicity.
Patient j’s datum will be used to update the posteriordistribution of a0, fa0(a, data)
J. Alvarez Bayesian CRM
![Page 31: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/31.jpg)
introductionmodel
variations on CRM
Likelihood function
For one patient:
P (Yj = yj) = (ψ(xj , a))yj (1− ψ(xj , a))1−yj .
Based on the bernoulli pmf
J. Alvarez Bayesian CRM
![Page 32: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/32.jpg)
introductionmodel
variations on CRM
Bayes
posterior after observing jth patient:
fa0(a, dataj) =(ψ(xj , a))
yj (1− ψ(xj , a))1−yjfa0(a, dataj−1)∫∞0 (ψ(xj , u))yj (1− ψ(xj , u))1−yjfa0(u, dataj−1) du
J. Alvarez Bayesian CRM
![Page 33: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/33.jpg)
introductionmodel
variations on CRM
Choice of prior
Common priors for a0
gamma
uniform
lognormal
J. Alvarez Bayesian CRM
![Page 34: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/34.jpg)
introductionmodel
variations on CRM
Final estimate of MTD
Can be estimated in same way as the dose for each patient isdetermined, since each patient is treated with the currentestimate
Determined after last patient is observed, if prespecifiedmaximum n
J. Alvarez Bayesian CRM
![Page 35: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/35.jpg)
introductionmodel
variations on CRM
Variations
modified CRM
EWOC escalation with overdose control (Babb et al., 1998)
Intervals of toxicity (Neuenschwander et al., 2008)
J. Alvarez Bayesian CRM
![Page 36: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/36.jpg)
introductionmodel
variations on CRM
Reference
O’Quigley, J., Pepe, M., and Fisher, L. (1990).
Continual reassessment method: A practical design for phase 1 clinical trials in cancer.Biometrics, 46:43–48.
J. Alvarez Bayesian CRM
![Page 37: Introduction to the Bayesian continual reassessment method ...biostat.mc.vanderbilt.edu/wiki/pub/Main/JoAnnAlvarez/crmPres.pdf · Introduction to the Bayesian continual reassessment](https://reader030.vdocuments.us/reader030/viewer/2022020120/5aa606fa7f8b9ab4788deec6/html5/thumbnails/37.jpg)
introductionmodel
variations on CRM
Standardized doses
Calculated based on
the probabilities of toxicity that the docs think the set ofstudy doses have
the assumed dose-response model
an initial estimate of a0
This info would be based on previous studies.
J. Alvarez Bayesian CRM